Can you please provide some early ovarian cancer diagnosis?
Transabdominal ultrasound screening for early ovarian cancer. S. Campbell, V. Bhan, P. Royston, M. I. Whitehead, W. P. Collins Department of Obstetrics and Gynaecology, King’s College School of Medicine and Dentistry, London. OBJECTIVE–To assess the value of ultrasonography in a screening procedure for early ovarian cancer. DESIGN–Prospective study of at least 5000 self referred women without symptoms of ovarian cancer. Each woman was scheduled to undergo three annual screenings (consisting of one or more scans) to detect grossly abnormal ovaries or non-regressing masses. SETTING–The ovarian screening clinic at King’s College Hospital, London. SUBJECTS–5479 Self referred women without symptoms (aged 18-78, mean age 52). INTERVENTIONS–Women with a positive result on screening were referred for laparoscopy or laparotomy, or both. MAIN OUTCOME MEASURES–Findings at surgery and from histology of abnormal ovaries. RESULTS–A total of 14,594 screenings (15,977 scans) were performed. A p
The inability to detect small ovarian tumors emphasizes the need for cancer-specific biomarkers that can detect more tumors at a curable stage, researchers suggested after analyzing statistical models of cancer growth, progression, and detection. To achieve even 50% sensitivity, a biomarker assay would have to detect serous tumors that are 1/200th as large as the clinically apparent tumors typically used to evaluate candidate biomarkers, investigators reported online in PLoS Medicine. However, the study also showed that the window of opportunity for detecting curable, serous ovarian cancer is surprisingly long. Sources: http://www.medpagetoday.
The inability to detect small ovarian tumors emphasizes the need for cancer-specific biomarkers that can detect more tumors at a curable stage, researchers suggested after analyzing statistical models of cancer growth, progression, and detection. To achieve even 50% sensitivity, a biomarker assay would have to detect serous tumors that are 1/200th as large as the clinically apparent tumors typically used to evaluate candidate biomarkers, investigators reported online in PLoS Medicine. Sources: http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.
